Previous studies provided evidence that pharmacological or genetic inactivation of MAGL alleviates neuropathology and improves synaptic and cognitive functions in several animal models of neurodegenerative diseases [21, 23–28]. This evidence concerns the gene MGLL and neurodegenerative disease.